DRD5 and myelodysplastic syndrome: We therefore interrogated the cellular effect of the treatment with DR antagonists such as SCH-23390 (SC90) (DRD1 and DRD5 antagonists), UH-232 (DRD2 and DRD3 antagonist), chlorpromazine (CPZ) (pan-DR antagonist), and thioridazine (Thio) (pan-DR antagonist) in MDS.